Corifollitropin Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Corifollitropin alfa: From Assisted Reproduction to Gastroduodenitis
One-Sentence Summary
Corifollitropin alfa is a long-acting recombinant follicle-stimulating hormone (FSH) analogue marketed in Singapore as Elonva. The TxGNN model predicts it may be effective for gastroduodenitis, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, corifollitropin alfa is a long-acting FSH analogue (an FSH beta-subunit fused with the C-terminal peptide of hCG). It acts on FSH receptors in the gonads.
No plausible mechanistic link to inflammation of the stomach and duodenal lining is evident. FSH receptor agonism has no known effect on gastric mucosal defence or acid-related injury. The high score (0.9965) appears to be a network-based prediction without clinical or literature support. It is probably an artefact of knowledge-graph proximity rather than independent biology.
Other top-ranked predictions show the same pattern. They include migraine disorders, peptic ulcer disease, Raynaud disease, pulmonary hypertension, and others. None has any trial or publication evidence, and none has a credible mechanistic rationale. Some are more concerning than promising. For example, ovarian stimulation changes oestradiol levels, which may trigger migraine rather than treat it, and ovarian hyperstimulation carries fluid-shift and thromboembolic risks relevant to pulmonary hypertension.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13940P | Elonva Solution for Injection 150mcg/0.5ml | Injection, solution | Not listed in the licence record |
| SIN13939P | Elonva Solution for Injection 100mcg/0.5ml | Injection, solution | Not listed in the licence record |
Both licences are valid single-ingredient products from Vetter Pharma-Fertigung GmbH & Co. KG.
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found for this drug in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. There are no clinical trials or publications, and the proposed indication has no plausible mechanistic link to an FSH receptor agonist. Safety information from the package insert is also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website, which are required for any safety screening
- Mechanism of action data (for example from DrugBank)
- The approved indication text for the Singapore licences
- Any preclinical or clinical evidence linking FSH receptor signalling to gastroduodenal disease
- A route and formulation compatibility assessment, since the product is an injectable intended for reproductive use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.